Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer 1Q Revenues Down 20% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Pfizer 1Q Revenues Down 20%

Decline in Comirnaty and Paxlovid revenues drove 19% operational decrease in revenues.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer 
1Q Revenues: $14.9 billion (-20%)
1Q Earnings: $3.1 billion (-44%)
Comments: Global biopharmaceutical sales were $14.6 billion in the quarter, down 20%. Decline in Comirnaty and Paxlovid revenues drove 19% operational decrease in revenues. Comirnaty sales were $354 million, down 88% and Paxlovid sales were $2.0 billion down 50%. Global revenues from legacy Seagen, which was acquired in December of 2023, were $742 million. Vyndaqel family sales were $1.1 billion, up 66%. Eliquis sales were $2.0 billion in the quarter, up 9%. Prevnar sales were $1.7 billion, up 7%. Ibrance sales were down 8% to $1.05 billion. Oncology biosimilars sales were down 36%, largely due to lower net price in the U.S. Sulperazon internationally, was down 45% operationally, driven largely by lower demand in China.
                  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters